

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.: 91120000103100784F)
(Incorporated in the People's Republic of China)

THE PROPOSED CAPITAL INJECTION OF RMB493,617,700 INTO TIANJIN PHARMACEUTICAL GROUP TAIPING MEDICINE CO., LTD. (津药太平医药有限公司) BY THE COMPANY THROUGH THE TRANSFER OF THE 100% EQUITY INTEREST IN THE REGISTERED CAPITAL OF TIANJIN ZHONGXIN MEDICINE CO., LTD. (天津中新医药有限公司) TO TIANJIN PHARMACEUTICAL GROUP TAIPING MEDICINE CO., LTD. (津药太平医药有限公司) AND THE PROPOSED ENTRY INTO A CAPITAL INJECTION AGREEMENT IN RELATION THERETO AS AN INTERESTED PERSON TRANSACTION

— COMPLETION OF THE PROPOSED CAPITAL INJECTION

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to:

- (a) the announcement dated 11 September 2024 made by the Company in relation to the resolutions passed at the 5th Board meeting for the financial year ending 31 December 2024;
- (b) the announcement dated 11 September 2024 made by the Company in relation to, amongst others, the proposed capital injection of RMB493,617,700 into Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) (“**Taiping Medicine**”) through the transfer of the 100% equity interest in the registered capital of Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) (“**TJZX Medicine**”) to Taiping Medicine (the “**Proposed Capital Injection**”) and the proposed entry into a capital injection agreement in relation thereto as an interested person transaction;
- (c) the circular dated 14 October 2024 (the “**Circular**”) to the Shareholders of the Company in relation to, amongst others, the Proposed Capital Injection and the proposed entry into a capital injection agreement in relation thereto as an interested person transaction; and
- (d) the announcement dated 29 October 2024 made by the Company in relation to the poll results of the extraordinary general meeting of the Company held on 29 October 2024.

Unless otherwise defined, all capitalised terms used and not defined herein shall have the same meanings as ascribed to them in the Circular.

2. COMPLETION OF THE PROPOSED CAPITAL INJECTION

The Board wishes to announce that Taiping Medicine and TJZX Medicine have respectively completed the industrial and commercial registration procedures in respect of the Proposed Capital Injection. Accordingly, the Proposed Capital Injection has been completed as at the date of this announcement.

Following the completion of the Proposed Capital Injection, TJZX Medicine has ceased to be a wholly-owned subsidiary of the Company and has become a wholly-owned subsidiary of Taiping Medicine, which is jointly held by the Company and TPH with 43.35% and 56.65% equity interests, respectively. As a result, the Company is now an indirect shareholder with a 43.35% equity interest in TJZX Medicine. In addition, Taiping Medicine is now an associated company (as defined in the Listing Manual) of the Company.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
26 December 2024